Currently out of the existing stock ratings of Mike Matson, 547 are a BUY (94.31%), 29 are a HOLD (5%), 4 are a SELL (0.69%).

Mike Matson

Work Performance Price Targets & Ratings Chart

Analyst Mike Matson works at NEEDHAM with a stock forecast success ratio of 55.14% fulfilled within 251.7 days on average.

Mike Matson’s has documented 1,026 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AORT, Artivion at 08-Apr-2024.

Wall Street Analyst Mike Matson

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/9/2023. The price target of $3.6 was fulfilled within 6 days with a profit of $0.9 (33.33%) receiving and performance score of 55.56.

Average potential price target upside

of $47.9 (25.25%) on PEN (PENUMBRA).
of $44.38 (17.1%) on TFX (TELEFLEX ORPORATED).
of $44.28 (20.67%) on SWAV (SHOCKWAVE MEDICAL).

ATRC AtriCure AXNX Axonics Modulation Technologies CNMD CONMED FNA Paragon 28 GMED Globus Medical HAE Haemonetics HRC Hill-Rom Holdings INMD InMode Ltd KIDS Orthopediatrics Corp LIVN LivaNova PLC LUCD Lucid Diagnostics MDT Medtronic PLC MMSI Merit Medical Systems NUVA NuVasive RMD ResMed SRDX SurModics SYK Stryker TFX Teleflex orporated VCYT Veracyte ZBH Zimmer Biomet Holdings BSX Boston Scientific Corp CSII Cardiovascular Systems GNMK GenMark Diagnostics HOLX Hologic INGN Inogen MDXG MiMedx Group NEO NeoGenomics OCX OncoCyte Corp CRY CryoLife STE STERIS plc WMGI Wright Medical Group N.V AORT Artivion PSNL Personalis PEN Penumbra MASI Masimo CMD Cantel Medical Corp IVC Invacare SWAV Shockwave Medical ENOV Enovis Corp NARI Inari Medical

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Mike Matson (NEEDHAM)